Researchers of this phase II clinical trial are investigating the effectiveness and safety of avatrombopag to treat pediatric ITP. Specifically, they are recruiting participants who have previously taken eltrombopag and switched to avatrombopag for reasons including ineffectiveness, side effects, platelet count fluctuation, economic reasons, or patient preference. Avatrombopag is a thrombopoietin receptor agonist, a class of drugs that stimulates the body to produce platelets.
This clinical trial is recruiting pediatric ITP patients aged 6-18 who have been diagnosed with primary ITP who has switched from eltrombopag to avatrombopag. Participants not eligible to participate include those who have secondary ITP, or diseases of the liver, kidney, heart or immune system, allergic to avatrombopag, or those who have had a splenectomy or used rituximab in the preceding 3 months.
The study will be conducted for 12 weeks, with a “response” to avatrombopag considered to be a platelet count ≥ 30,000 and at least 2x increased from baseline without bleeding or the need for rescue therapy.
China
Actively Recruiting